Vitrolife

First quarter 

• Sales of SEK 842 (841) million, an increase of 1% in local currencies and 0% in SEK. The growth in local currencies excluding discontinued business was 3%. 
• Sales per region, in local currencies was +8% in EMEA, +14% excluding discontinued business, +9% in Americas and -15% in APAC. 
• Sales per product groups, in local currencies excluding discontinued business was +6% in Consumables, -5% in Technologies and +4% in Genetics. 
• Sales per product groups, in local currencies was +3% in Consumables, -6% in Technologies and +1% in Genetics. 
• Gross margin increased to 57.4% (57.1). 
• Earnings before depreciation and amortisation (EBITDA) decreased to SEK 257 (272) million, giving an EBITDA margin of 30.6% (32.4), affected by foreign exchange impact of SEK -13 (1) million. 
• Operating cash flow amounted to SEK 69 million (198). 
• Net income was SEK 100 (115) million, resulting in earnings per share of SEK 0.74 (0.85).

Gothenburg, April 24, 2025
VITROLIFE AB (publ)
Bronwyn Brophy O´Connor, CEO